The principal investigators for the study are Dean Tang, associate professor of division of carcinogenesis and adjunct associate professor of college of pharmacy at The University of Texas
Sequenom has previously announced that it would terminate the exchange offer if Exact Sciences entered into any out-licensing agreement, collaboration or financial restructuring. Sequenom continues to be committed
Taro has received tentative approval for this abbreviated new drug application (ANDA) in March 2008. Lamotrigine is a prescription product used for the treatment of seizures and is
The company has also delivered the GMP grade product to Neogenix in preparation for Phase I/II clinical trials planned for the first half of 2009. NPC-1C is a
The study has demonstrated that repeat intravenous treatment with pegylated-rHuPH20 enzyme (PEGPH20) as a single agent in the PC3 mouse model resulted in approximately 70% (p=0.001) tumor growth
The reduction in workforce will extend the company’s existing cash resources to fund operations until around the end of 2009. The measures are expected to be implemented with
In Australia, Meridian has signed an agreement with Sydney-based Immuno. For Argentina, Meridian has signed with Scott Pharma, a healthcare distributor. This decision is consistent with Meridian’s stated
The Phase III multi-center, randomized, double-blind, placebo-controlled trial in approximately 850 migraine sufferers is evaluating the safety and efficacy of MAP0004 as a potential acute treatment for migraine.
In this role, Dr Vaishnaw will be responsible for continued leadership of the company’s clinical activities; he will continue to report to John Maraganore, Alnylam’s CEO. Dr Vaishnaw
This agreement is in addition to the prior one announced in July 2007 to develop a novel stent system for coronary artery disease, which is now in clinical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.